[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 186″]
With Oyster Point Pharma announcing results from the Phase IIb PEARL study, company president and CEO Jeffrey Nau, PhD, talks with OIS Podcast about what the findings mean for OC-02, a nicotinic acetylcholine receptor agonist the company is developing to treat the signs and symptoms of dry eye disease. The study met both primary endpoints by showing a statistically significant improvement in signs and symptoms compared with control. Top-line data from the study will be presented this weekend at the American-European Congress of Ophthalmic Surgery Summer Symposium in Deer Valley, UT. OC-02 is delivered as a nasal spray and stimulates the trigeminal parasympathetic pathway to activate the glands responsible for producing the eye’s natural tear film.